Biomedicine

Start of Clinical Research with Hiroshima University on Photon-Counting CT

Retrieved on: 
Tuesday, April 9, 2024
Biomedicine, X-ray, Congress, Medicine, Ōtawara, Medical imaging, Research, Canon Medical Systems Corporation, Society, Deep learning, Outline of health sciences, Hiroshima University

Tustin, California, April 09, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) and Hiroshima University (President: Mitsuo Ochi; location: Higashi-Hiroshima, Hiroshima, Japan) began clinical research.

Key Points: 
  • Tustin, California, April 09, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) and Hiroshima University (President: Mitsuo Ochi; location: Higashi-Hiroshima, Hiroshima, Japan) began clinical research.
  • PCCT is expected to become the next generation of X-ray CT.
    Canon Medical entered into a basic agreement on joint clinical research with Hiroshima University on November 1, 2023, *1 and clinical research began, led by Professor Kazuo Awai of the Department of Diagnostic Radiology at Hiroshima University Graduate School of Biomedical and Health Sciences.
  • Through this latest clinical research, we are aiming to take another step forward towards the practical application of PCCT.
  • We will accelerate development of PCCT by feeding back the results of this clinical research into improvement of the system.

Syntec Optics (Nasdaq: OPTX) to Showcase Advanced Imaging and Sensing Technologies at SPIE Defense + Commercial Sensing 2024

Retrieved on: 
Friday, April 5, 2024
LEO, Communication, Biomedicine, Original equipment manufacturer, Acquisition, Commercial, DCS, Defense

At booth #938, Syntec Optics will demonstrate its latest breakthroughs, engage with valued customers, and ignite further partnerships within the vibrant defense and sensing community.

Key Points: 
  • At booth #938, Syntec Optics will demonstrate its latest breakthroughs, engage with valued customers, and ignite further partnerships within the vibrant defense and sensing community.
  • "Syntec Optics has announced and launched several new products for existing markets and customers using existing capabilities," said Sara Hart, Director of Sales at Syntec Optics.
  • Ultra-Precision Biomedical Optics: Revolutionize medical imaging and diagnostics with Syntec Optics' state-of-the-art biomedical optics solutions.
  • Visit Syntec Optics at booth #938 during DCS 2024 to immerse yourself in a world of transformative light-based technologies.

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Risk management, Certification, Biomedicine, Biomedical engineering, University, Diabetes, Senior management, Class, Commercial, Quality management system, Doctor of Philosophy, Process validation, Bachelor, Quality management, Sustainability, ISO, FDA

He will lead ISO-13485 certification and all related quality activities for the Company’s implantable Continuous Blood Glucose Monitoring (CBGM) technology.

Key Points: 
  • He will lead ISO-13485 certification and all related quality activities for the Company’s implantable Continuous Blood Glucose Monitoring (CBGM) technology.
  • “We are thrilled that Vincent has joined our growing team in this important leadership role.” said Paul Goode, PhD, CEO of Glucotrack.
  • Implementing a sustainable Quality Management System that will grow with us is essential as we now embark on product development activities for our commercial product.
  • I look forward to joining this leadership team to bring this differentiated technology to people with diabetes,” said Mr. Wong.

Juniper Biomedical Secures Seed Funding to Accelerate Growth and Innovation in Pelvic Health Disorders.

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Professional Services, Health, General Health, Women, Venture Capital, Health Technology, Other Science, Medical Devices, Consumer, Science, Biomedicine, Growth, Urinary incontinence, Entrepreneurship, MUI, Patient, Pelvic pain, Incontinence, NIH, Woman, Ecosystem, Medtech, Pharmaceutical industry

The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.

Key Points: 
  • The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.
  • "We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," said Larry Derose, founder of Auroral Holdings.
  • Juniper Biomedical is developing dramatically better therapies for the millions of women and men who suffer in silence from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders.
  • Our solutions leverage a highly precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves.

Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board

Retrieved on: 
Tuesday, April 2, 2024
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Principal, Harvard Medical School, Education, DSM-IV codes, Associate, Nanoparticle, Patient, Biomedicine, RNA, Flagship Pioneering, Columbia University, AI, Faculty, Personalized medicine, Panasonic Executive Partner, Infection, Hospital, Division, Therapy, Medical director, Genomics, Nursing

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.

Key Points: 
  • Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.
  • Dr. Chung currently serves as Chief of the Department of Pediatrics of Boston Children’s Hospital, sits on the faculty at Harvard Medical School, and is President of the Children’s Hospital Pediatric Associates.
  • Dr. Chung brings to Sail’s board more than 20 years of experience as a clinical and molecular geneticist, as well as biotech operational experience.
  • “I’m thrilled to contribute to Sail’s mission to create breakthroughs for patients with new types of RNA therapeutics and to join Sail’s distinguished Board of Directors,” said Dr. Chung.

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

The Inner Circle acknowledges Jennifer A. Vazquez as a Pinnacle Lifetime Member

Retrieved on: 
Thursday, April 4, 2024
Kentucky Association, Biomedicine, Biomedical engineering, University, Biomedical technology, Growth, Projection, Central Florida, Learning, Knowledge, USB On-The-Go, AAMI, Biomedical equipment technician, DeVry University, Health technology, Health, Inner circle

CINCINNATI, April 4, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jennifer A. Vazquez is acknowledged as a Pinnacle Lifetime Member for her contributions in Medical Technology.

Key Points: 
  • CINCINNATI, April 4, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jennifer A. Vazquez is acknowledged as a Pinnacle Lifetime Member for her contributions in Medical Technology.
  • Jennifer A. Vazquez, a dynamic professional in the field of medical technology, has garnered recognition for her exceptional contributions and achievements in biomedical engineering.
  • With an impressive educational background and a commitment to excellence, Jennifer has established herself as a rising star in the industry.
  • Jennifer A. Vazquez attributes her success to the guidance and mentorship she has received from individuals such as Mr. Edward Reyes and Mr. Enrique Vazquez.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."